Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock (or pre-funded warrants) with concurrent unregistered short-term warrants Closed: US$2.5M raised · US$3.03 a share · Warrants at US$2.78 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Apr 16, 2026 |
| Warrant exercise of existing warrants exercised for shares of common stock Announced: about US$2.67M · US$0.6 a share · Warrants at US$0.425 for 60 months Use of proceeds: Working capital and general corporate purposes | Jun 17, 2025 |
| Equity line of credit Announced: raise Buyers: Lincoln Park Capital (equity line of credit for up to $12 million of additional funding) | May 13, 2025 |
| Registered direct offering of shares of common stock with unregistered short-term warrants Closed: US$1.1M raised · US$0.4 a share · Warrants at US$0.4 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Mar 10, 2025 |
| Registered direct offering of shares of common stock with unregistered warrants Announced: about US$2.5M · US$1.015 a share · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Jan 6, 2025 |